UK approves Lilly’s Alzheimer’s drug but labels it ‘too expensive’ for NHS use

The UK has approved Eli Lilly's new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and ... Read More